Payment overview · 2025
General Payments
$817.81
18 reported records · 8 companies
Healthcare provider profile · identity verified
Amarilis Corchado Perez, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ISABELA, PR · NPI 1437357621
Verified facts
What the public records show
CMS Open Payments records show Amarilis Corchado Perez, MD received $817.81 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuplazid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $218.62 | 26.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $135.25 | 16.5% | 7 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $112.49 | 13.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $108.09 | 13.2% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $99.64 | 12.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.57 | 11.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.80 | 3.3% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.35 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.81 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $218.62 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $135.25 | 7 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $112.49 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $108.09 | 4 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $99.64 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $90.57 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 3715 | 509 |
| Donepezil Hcl | Donepezil Hcl | 2392 | 418 |
| Memantine Hcl | Memantine Hcl | 1555 | 252 |
| Pregabalin | Pregabalin | 1149 | 189 |
| Diclofenac Sodium | Diclofenac Sodium | 841 | 149 |
| Tizanidine Hcl | Tizanidine Hcl | 771 | 137 |
| Escitalopram Oxalate | Escitalopram Oxalate | 671 | 122 |
| Rivastigmine | Rivastigmine | 640 | 107 |
| Meloxicam | Meloxicam | 579 | 122 |
| Citalopram Hbr | Citalopram Hydrobromide | 575 | 99 |
| Duloxetine Hcl | Duloxetine Hcl | 513 | 85 |
| Levetiracetam | Levetiracetam | 499 | 55 |
| Topiramate | Topiramate | 421 | 61 |
| Clonazepam | Clonazepam | 398 | 61 |
| Temazepam | Temazepam | 364 | 79 |
| Rizatriptan | Rizatriptan Benzoate | 343 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 329 | 64 |
| Divalproex Sodium Er | Divalproex Sodium | 329 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 54 |
| Diclofenac Potassium | Diclofenac Potassium | 293 | 55 |
| Primidone | Primidone | 286 | 45 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 272 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 269 | 41 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 250 | 37 |
| Famotidine | Famotidine | 249 | 43 |
| Lamotrigine | Lamotrigine | 241 | 32 |
| Baclofen | Baclofen | 228 | 40 |
| Emgality Pen | Galcanezumab-Gnlm | 228 | 25 |
| Nabumetone | Nabumetone | 212 | 38 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 197 | 36 |
| Sumatriptan Succinate | Sumatriptan Succinate | 172 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 163 | 27 |
| Propranolol Hcl | Propranolol Hcl | 163 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 152 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 23 |
| Sulindac | Sulindac | 139 | 26 |
| Carbamazepine Er | Carbamazepine | 136 | 22 |
| Buspirone Hcl | Buspirone Hcl | 135 | 31 |
| Synthroid | Levothyroxine Sodium | 131 | 24 |
| Savella | Milnacipran Hcl | 127 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 27 |
| Bupropion Xl | Bupropion Hcl | 116 | 20 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 109 | 16 |
| Lorazepam | Lorazepam | 108 | 26 |
| Rasagiline Mesylate | Rasagiline Mesylate | 105 | 13 |
| Amantadine | Amantadine Hcl | 102 | 18 |
| Sertraline Hcl | Sertraline Hcl | 99 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 98 | 19 |
| Tramadol Hcl | Tramadol Hcl | 84 | 52 |
| Etodolac Er | Etodolac | 81 | 13 |
| Oxcarbazepine | Oxcarbazepine | 79 | suppressed |
| Simvastatin | Simvastatin | 78 | 12 |
| Galantamine Er | Galantamine Hbr | 74 | suppressed |
| Ezetimibe | Ezetimibe | 70 | 11 |
| Alprazolam | Alprazolam | 69 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 15 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 69 | 44 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 65 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 62 | suppressed |
| Lansoprazole | Lansoprazole | 61 | suppressed |
| Omeprazole | Omeprazole | 60 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 59 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 49 | suppressed |
| Risperidone | Risperidone | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | suppressed |
| Gemfibrozil | Gemfibrozil | 47 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Phenobarbital | Phenobarbital | 41 | suppressed |
| Keppra | Levetiracetam | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 37 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Estazolam | Estazolam | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 30 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Ciclopirox | Ciclopirox | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Losartan Potassium | Losartan Potassium | 24 | suppressed |
| Cabergoline | Cabergoline | 23 | suppressed |
| Lisinopril | Lisinopril | 23 | suppressed |
| Ubrelvy | Ubrogepant | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 22 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Tegretol Xr | Carbamazepine | 21 | suppressed |
| Zonisamide | Zonisamide | 21 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 20 | suppressed |
| Levetiracetam Er | Levetiracetam | 20 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Metaxalone | Metaxalone | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Betaseron | Interferon Beta-1b | 11 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Onfi | Clobazam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $817.81 · 18 records | Lilly USA, LLC | CREXONT, INVEGA SUSTENNA, KESIMPTA, KISUNLA, NUPLAZID, QULIPTA, SKYCLARYS, TYSABRI, UBRELVY, UPLIZNA, VUMERITY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error